

Oral Abstract Presentation

DAY 1 - Room B

November 25(Fri.)

Time	Program	Name	Affiliation
Session 4	Oral Abstract Presentation (1)	Chair	Taek Sang Kim Kosin University
		Chair	Tomokazu Kimura University of Tsukuba
14:00~14:05	O-001. Efficacy of the novel irrigation procedure for f-TUL “the CARP (Continuous Active Reduction of the internal Pressure in the renal pelvis) method” in the patients with >20mm renal calculus: pilot study	Speaker	Reina Kono Ehime University Hospital
14:05~14:10	O-002. Treatment modality of prostatic abscess according to size : retrospective study	Speaker	Gwon Kyeong Lee Pusan National University Hospital
14:10~14:15	O-003. Healthy young men have a diurnal difference of maximum urine flow rate in a controlled environment room.	Speaker	Hiromitsu Negoro University of Tsukuba
14:15~14:20	O-004. Recurrence of Interstitial Cystitis/Bladder Pain Syndrome with Hunner Lesion after Postoperative Intravesical Hyaluronic Acid and Chondroitin Sulfate Instillation Therapy	Speaker	Kwang Jin Ko Samsung Medical Center
14:20~14:25	O-005. Exosomal molecules as a target for therapy and diagnosis in renal cell carcinoma	Speaker	Hirofumi Yoshino Kagoshima University
14:25~14:30	O-006. Robot assisted Partial Nephrectomy for T1b Tumors : A single center experience	Speaker	Masashi Takenaka Fujita Health University
14:30~14:35	O-007. Robotic versus open partial nephrectomy for the management of over T2 renal cell carcinoma in patients with solitary kidney	Speaker	Soodong Kim Dong-A University
14:35~14:40	O-008. Object Detection system for Bladder Tumors in White light and Narrow-Band Imaging Cystoscopic Images by artificial intelligence	Speaker	Jun Mutaguchi Kyushu University Hospital
14:40~14:45	O-009. Outcome of half-dose Bacillus Calmette-Guérin maintenance therapy for high-risk non-muscle invasive bladder cancer	Speaker	Maki Yamakawa Ehime University Hospital
14:45~14:50	O-010. Impact of immune-related adverse events on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma with adjustment for immortal time bias	Speaker	Yuki Kita Kyoto University
14:50~14:55	O-011. Changes of exosomal urinary PD-L1 concentration after PD-L1 inhibitor therapy in metastatic bladder cancer patients refractory to cisplatin based chemotherapy	Speaker	Kyung Hwan Kim Pusan National University Hospital
14:55~15:00	O-012. Adjuvant systemic chemotherapy after radical nephroureterectomy for upper urinary tract urothelial carcinoma reduces postoperative intravesical recurrence	Speaker	Noriya Yamaguchi Tottori University
15:00~15:05	O-013. IL-7 and CCL19 producing CAR-T cells enhance antitumor efficacy against solid cancer by preventing antigen-loss tumor relapse	Speaker	Shunsuke Goto Kyushu University
Session 5	Oral Abstract Presentation (2)	Chair	Young-Hwii Ko Yeungnam University Hospital
		Chair	Hiromitsu Negoro University of Tsukuba
15:30~15:35	O-014. The feasibility of molecular profiling of prostate tissue samples obtained from patients with metastatic castration-resistant prostate cancer	Speaker	Takayuki Sumiyoshi Kyoto University
15:35~15:40	O-015. Impact of the COVID-19 Pandemic on Prostate Cancer: Does it cause Prostate Cancer to be diagnosed at a more advanced stage?	Speaker	Byeong Jin Kang Pusan National University Hospital
15:40~15:45	O-016. Evaluation of the accuracy of MRI/TRUS fusion-guided biopsy for assessment of IT (Index Tumor) using postoperative pathology specimens.	Speaker	Atsushi Yamamoto Tottori University
15:45~15:50	O-017. Comparison of MR-guided prostate biopsy and Systematic prostate biopsy : Regarding clinically significant prostate cancer and cancer core positivity	Speaker	Kyoungha Jang Pusan National University Hospital
15:50~15:55	O-018. Prediction of changes in clinical practice following the introduction of Ga-68 PSMA-11 PET/CT for prostate cancer in Korea: 230 cases preliminary report	Speaker	Si Hyun Kim Seoul National University Hospital
15:55~16:00	O-019. Factors predicting detection of clinically significant prostate cancer when performing re-biopsy with TRUS-MR fusion biopsy: Propensity Score Matching	Speaker	Si Hyun Kim Seoul National University Hospital
16:00~16:05	O-020. The comparative outcome of extraperitoneal SP RARP vs transperitoneal multiport RARP	Speaker	Young Hwii Ko Yeungnam University
16:05~16:10	O-021. Initial experience of SpaceOAR® in proton therapy for prostate cancer	Speaker	Tomokazu Kimura University of Tsukuba
16:10~16:15	O-022. Is Focal treatment of prostate cancer safe? based on comprehensive per lesion analysis	Speaker	Jang Hee Han Seoul National University Hospital
16:15~16:20	O-023. The impact of pharmacogenomic features on adverse events in patients with prostate cancer treated with abiraterone acetate	Speaker	Yoshiko Takahashi Akita University
16:20~16:25	O-024. The influence of radiographic disappearance of metastasis on the efficacy and prognosis of patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy or combined androgen blockade.	Speaker	Kohei Hashimoto Sapporo Medical University
16:25~16:30	O-025. Short-Term Lower Urinary Tract and Defecation Symptoms with and without Hydrogel Spacer after Radiotherapy for Prostate Cancer	Speaker	Emika Moriyasu Tottori University
16:30~16:35	O-026. Imipramine inhibits prostate cancer progression through inducing apoptosis of prostate cancer cells	Speaker	Seung-hwan Jeong Seoul National University Hospital